Pune, India

Pavan Kardile

This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Gennova Biopharmaceuticals Limited. Active years: 2019.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Pavan Kardile: Innovator in Biopharmaceuticals

Introduction

Pavan Kardile is a notable inventor based in Pune, India. He has made significant contributions to the field of biopharmaceuticals, particularly in the purification processes of recombinant proteins. His work is characterized by a commitment to innovation and industrial viability.

Latest Patents

Pavan Kardile holds a patent for a process titled "Process for purification of rHu-GCSF." This invention provides a novel, scalable, and industrially viable downstream process for the purification of recombinant human G-CSF. His patent demonstrates his expertise in developing efficient methods that can be applied in the biopharmaceutical industry.

Career Highlights

Kardile is currently employed at Gennova Biopharmaceuticals Limited, where he continues to advance his research and development efforts. His work at Gennova focuses on creating innovative solutions that enhance the production and purification of biopharmaceuticals.

Collaborations

Pavan collaborates with talented professionals in his field, including Arjun Raghuwanshi and Shrawan Kumar Singh. These collaborations foster a creative environment that encourages the exchange of ideas and expertise.

Conclusion

Pavan Kardile is a distinguished inventor whose work in biopharmaceuticals is paving the way for advancements in protein purification. His contributions are vital to the ongoing evolution of the industry, and his innovative spirit continues to inspire those around him.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…